Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 4846 AL 4860

Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease

Leclerc B, Abulrob A.

ScientificWorldJournal. 2013;2013:589308. doi: 10.1155/2013/589308. Epub 2013 Feb 5.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. doi: 10.2174/1574889811308010006.

Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria

Sperling R, Johnson K.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):325-38. doi: 10.1212/01.CON.0000429181.60095.99.

Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process

Stefani A, Olivola E, Stampanoni Bassi M, Pisani V, Imbriani P, Pisani A, Pierantozzi M.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):538-46. doi: 10.2174/1871527311312040016.

Smell identification function as a severity and progression marker in Alzheimer's disease

Velayudhan L, Pritchard M, Powell JF, Proitsi P, Lovestone S.

Int Psychogeriatr. 2013 Jul;25(7):1157-66. doi: 10.1017/S1041610213000446. Epub 2013 Apr 19.

Alzheimer's disease biomarkers: correspondence between human studies and animal models

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Dis. 2013 Aug;56:116-30. doi: 10.1016/j.nbd.2013.04.010. Epub 2013 Apr 28.

Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease

Schmitt A, Falkai P.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):271-2. doi: 10.1007/s00406-013-0409-0.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1.

Clinical trials in predementia stages of Alzheimer disease

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.

Applying the IWG research criteria in clinical practice: feasibility and ethical issues

Molinuevo JL, Rami L.

Med Clin North Am. 2013 May;97(3):477-84. doi: 10.1016/j.mcna.2012.12.018. Epub 2013 Feb 1.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170.

Ushering in the study and treatment of preclinical Alzheimer disease

Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, Caselli RJ, Tariot PN, Reiman EM.

Nat Rev Neurol. 2013 Jul;9(7):371-81. doi: 10.1038/nrneurol.2013.107. Epub 2013 Jun 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias